News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arcutis Biotherapeutics, Inc.
< Previous
1
2
Next >
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Proposed Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.